CRP and systemic sclerosis: In conclusion, rosuvastatin improves brachial artery FMD, corrects dyslipidemia and decreases CRP, complement 3 and 4 and immune complex levels, while it may not reduce arterial stiffness or carotid atherosclerosis following a six-month treatment period in SSc patients with intermediate cardiovascular risk.